Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
02 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/02/3109090/0/en/BriaCell-Highlights-Additional-Phase-3-Clinical-Sites-Including-Los-Angeles-Cancer-Network-and-Smilow-Cancer-Hospital-at-Yale-New-Haven.html
24 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/24/3104139/0/en/BriaCell-Announces-Positive-Recommendation-from-Data-Safety-Monitoring-Board-for-Pivotal-Phase-3-Study-in-Metastatic-Breast-Cancer.html
04 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/04/3093465/0/en/BriaCell-Announces-Virtual-Investor-Presentations-on-Thursday-June-12-and-Thursday-June-26.html
02 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/02/3091756/0/en/BriaCell-Reports-Robust-Overall-Survival-and-Clinical-Benefit-Data-at-ASCO-2025.html
27 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/27/3088507/0/en/BriaCell-Bria-OTS-Phase-1-2-Study-Clears-Safety-Evaluation-Doses-First-Patient-in-Combination-with-Checkpoint-Inhibitor.html
23 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/23/3087418/0/en/BriaCell-Abstracts-Showcase-Positive-Survival-and-Clinical-Benefit-Data-at-ASCO-2025.html
Details:
BriaCell Bria-IMT (SV-BR-1-GM) is being evaluated in the late-stage clinical trial studies for the treatment of breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide
Therapeutic Area: Oncology Brand Name: Bria-IMT
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2025
Lead Product(s) : SV-BR-1-GM,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Accelerates Enrollment in Phase 3 Breast Cancer Study Bria-ABC
Details : BriaCell Bria-IMT (SV-BR-1-GM) is being evaluated in the late-stage clinical trial studies for the treatment of breast cancer.
Product Name : Bria-IMT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 22, 2025
Details:
Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is being investigated with immune checkpoint inhibitor for treating breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area: Oncology Brand Name: Bria-IMT
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2025
Lead Product(s) : SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
Details : Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is being investigated with immune checkpoint inhibitor for treating breast cancer.
Product Name : Bria-IMT
Product Type : Vaccine
Upfront Cash : Inapplicable
April 16, 2025
Details:
BriaPro is developing novel, high affinity antibodies to B7-H3, a promising anti-cancer target for drugs both effecting cancer cells and blocking immune checkpoint activity.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
Details : BriaPro is developing novel, high affinity antibodies to B7-H3, a promising anti-cancer target for drugs both effecting cancer cells and blocking immune checkpoint activity.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 10, 2025
Details:
Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is being investigated with immune checkpoint inhibitor for treating breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area: Oncology Brand Name: Bria-IMT
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell’s Phase 3 Breast Cancer Study gets Positive Safety Board Review
Details : Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is being investigated with immune checkpoint inhibitor for treating breast cancer.
Product Name : Bria-IMT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 20, 2025
Details:
Bria-OTS is a personalized off-the-shelf next-gen immunotherapy, which is being evaluated as monotherapy and in combination Tislelizumab and cyclophosphamide for advanced metastatic breast cancer.
Lead Product(s): Bria-OTS,Cyclophosphamide,Tislelizumab
Therapeutic Area: Oncology Brand Name: Bria-OTS
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2025
Lead Product(s) : Bria-OTS,Cyclophosphamide,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Announces Resolution of Lung Metastasis in First Patient Treated with Bria-OTS™
Details : Bria-OTS is a personalized off-the-shelf next-gen immunotherapy, which is being evaluated as monotherapy and in combination Tislelizumab and cyclophosphamide for advanced metastatic breast cancer.
Product Name : Bria-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 03, 2025
Details:
Bria-IMT (SV-BR-1-GM) is a genetically engineered human breast cancer cell line with features of immune cells, being evaluated with retifanlimab for the treatment of advanced metastatic breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area: Oncology Brand Name: Bria-IMT
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2024
Lead Product(s) : SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Phase 3 Study in Metastatic Breast Cancer Cleared By Safety Board
Details : Bria-IMT (SV-BR-1-GM) is a genetically engineered human breast cancer cell line with features of immune cells, being evaluated with retifanlimab for the treatment of advanced metastatic breast cancer.
Product Name : Bria-IMT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 02, 2024
Details:
Bria-OTS is a personalized off-the-shelf next-gen immunotherapy, which is being evaluated as monotherapy and in combination Tislelizumab and cyclophosphamide for advanced metastatic breast cancer.
Lead Product(s): Bria-OTS,Cyclophosphamide,Tislelizumab
Therapeutic Area: Oncology Brand Name: Bria-OTS
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2024
Lead Product(s) : Bria-OTS,Cyclophosphamide,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study
Details : Bria-OTS is a personalized off-the-shelf next-gen immunotherapy, which is being evaluated as monotherapy and in combination Tislelizumab and cyclophosphamide for advanced metastatic breast cancer.
Product Name : Bria-OTS
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 21, 2024
Details:
Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is clinically used as a targeted immunotherapy for treating breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area: Oncology Brand Name: Bria-IMT
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2024
Lead Product(s) : SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Details : Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is clinically used as a targeted immunotherapy for treating breast cancer.
Product Name : Bria-IMT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 09, 2024
Details:
Bria-IMT (SV-BR-1-GM) is an off-the-shelf targeted cellular immunotherapy. It is being evaluated in combination with Zynyz (retifanlimab-dlwr) for the treatment of Metastatic breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area: Oncology Brand Name: Bria-IMT
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 22, 2024
Lead Product(s) : SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Reports Positive Data for Metastatic Breast Cancer Survival
Details : Bria-IMT (SV-BR-1-GM) is an off-the-shelf targeted cellular immunotherapy. It is being evaluated in combination with Zynyz (retifanlimab-dlwr) for the treatment of Metastatic breast cancer.
Product Name : Bria-IMT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 22, 2024
Details:
Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is clinically used as a targeted immunotherapy for treating breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area: Oncology Brand Name: Bria-IMT
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Provides Phase 3 Study Update in Metastatic Breast Cancer
Details : Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells. It is clinically used as a targeted immunotherapy for treating breast cancer.
Product Name : Bria-IMT
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 15, 2024
ABOUT THIS PAGE